On November 29, 2016 Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on Monday, Dec. 5, 2016, to discuss the poster presentation on its lead drug candidate, TTI-621, at the American Society of Hematology (ASH) (Free ASH Whitepaper) 58th Annual Meeting in San Diego (Filing, 6-K, Trillium Therapeutics, NOV 29, 2016, View Source [SID1234516828]). Trillium will present initial clinical data from its ongoing TTI-621 hematologic malignancy Phase 1 trial at ASH (Free ASH Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call may be accessed by dialing:

U.S. callers: (844) 358-6757
International callers: (216) 562-0400
Conference ID: 28772974.
The conference call will also be available via a live webcast on the investors section of Trillium’s website at www.trilliumtherapeutics.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. Following the call, an archived webcast replay will be available on the company’s website for three months.